Lyell Immunopharma, Inc. (LYEL) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Lyell Immunopharma, Inc. (LYEL) Earnings Overview
As of July 8, 2026, Lyell Immunopharma, Inc. (LYEL) reported trailing twelve-month net income of -$246M, reflecting -1126.0% year-over-year growth. The company earned $-11.26 per diluted share over the past four quarters, with a net profit margin of -762355.6%.
Looking at the long-term picture, LYEL's historical earnings data spans multiple years. The company achieved its highest annual net income of -$129M in fiscal 2019.
Lyell Immunopharma, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including FATE (-$130M net income, -2051.1% margin), ADCT (-$137M net income, -175.3% margin), CABA (-$175M net income), LYEL has room to improve margins relative to the peer group. Compare LYEL vs FATE →
LYEL Earnings vs Peers
Earnings metrics vs comparable public companies
LYEL Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$274M | +20.0% | -$204M | $-16.06 | -762355.6% | -566038.9% |
| 2024 | -$343M | -46.2% | -$359M | $-1.31 | -562285.2% | -588123.0% |
| 2023 | -$235M | -28.1% | -$247M | $-0.93 | -180486.2% | -190006.2% |
| 2022 | -$183M | +26.8% | -$187M | $-0.74 | -216.2% | -220.9% |
| 2021 | -$250M | -22.4% | -$215M | $-1.03 | -2349.5% | -2016.7% |
| 2020 | -$204M | -58.0% | -$212M | $-0.84 | -2636.3% | -2732.6% |
| 2019 | -$129M | - | -$102M | $-0.53 | -19692.1% | -15538.7% |
Download Data
Export LYEL earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
LYEL — Frequently Asked Questions
Quick answers to the most common questions about buying LYEL stock.
What is LYEL earnings per share (EPS)?
LYEL trailing twelve-month (TTM) diluted EPS is $-11.26, reflecting -1126.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is Lyell Immunopharma, Inc.'s net income?
Lyell Immunopharma, Inc. (LYEL) trailing twelve-month net income is $-246M as of 2025. Earnings declined -1126.0% year-over-year.
Is LYEL profitable?
LYEL is not currently profitable on a TTM basis, reporting a net loss of $-246M. Net margin is -762355.6%. Investors should monitor for a return to profitability.
What is LYEL's earnings growth rate?
LYEL compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are LYEL's profit margins?
Lyell Immunopharma, Inc. net profit margin is -762355.6%, operating margin is -566038.9%, and gross margin is -31952.8%. Below-average margins reflect competitive or cost pressures. Return on Equity is -87.0%.
Is LYEL growing earnings?
LYEL earnings are declining — EPS fell -1126.0% year-over-year. TTM net income dropped to $-246M. This contrasts with the 5-year CAGR of N/A.
What was LYEL's best earnings year?
Lyell Immunopharma, Inc.'s highest annual net income on record is $-129M, achieved in fiscal year 2019. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were LYEL's earnings last quarter?
LYEL's most recent reported quarter was Q1 2026. Net income was $-24M with diluted EPS of $-1.10. For a full breakdown of all quarters, see the quarterly earnings table on this page.